38 results about "Tumor formation" patented technology

The invention discloses a construction method and application of an animal model for evaluating cardiotoxicity of antitumor drugs, sodium carboxymethyl cellulose (CMC-Na) with extremely low cost is adopted to replace matrigel, a tumor-bearing mouse model with high stability can be constructed at low cost, and experimental verification shows that 4T1 cells are resuspended by using a 0.7% CMC-Na solution, and the tumor formation rate of subcutaneous inoculation reaches gt; 95%. The tumor microenvironment-mediated cardiac injury critical period is accurately captured, and the constructed tumor-bearing mouse model is the optimal tumor-bearing mouse model for evaluating the cardiotoxicity of an antitumor drug (adriamycin) in the tumor microenvironment in the third week after the mouse has a 50mm < 3 > tumor.

This invention relates to a method for constructing a mouse orthotopic model of highly aggregated glioblastoma, belonging to the fields of biomedicine and experimental animal model technology. Glioblastoma cells are resuspended in a composite carrier of a specific ratio of matrix gel and serum-free culture medium, and a low-temperature injection technique is used. Utilizing the thermosensitivity of matrix gel in the mouse intracranial environment (i.e., its phase transition from liquid to gel at a certain temperature), precise colonization and physical locking of tumor cells at target coordinate points are achieved. This method improves upon existing glioblastoma mouse orthotopic model construction techniques that suffer from tumor cell diffusion and loss, low tumor formation rate, irregular tumor morphology, large intragroup variability, and needle reflux due to low viscosity of the inoculation carrier. It provides a good disease model for subsequent screening or evaluation of anti-glioblastoma drugs.

The invention relates to application of WDR74 and / or ALYREF as molecular targets in esophageal squamous cell carcinoma diagnosis and treatment, and belongs to the technical field of biological medicine. Aiming at the problem that the esophageal squamous cell carcinoma lacks an effective targeted treatment means, the invention discovers that the expression quantity of WDR74 in tumor tissues is obviously higher than that in para-carcinoma tissues, and the high expression of WDR74 prompts poor prognosis of a patient, and reveals that WDR74 protein and ALYREF protein have specific binding, and the mRNA stability of EGFR is enhanced through ALYREF-mediated m5C RNA epigenetic modification, so that STAT3 phosphorylation is activated, and the treatment effect of the esophageal squamous cell carcinoma is enhanced. Further, the STAT3 is combined with the promoter region of the apoptosis-inhibiting gene MCL1, and finally cell apoptosis is inhibited and tumor formation is promoted. The invention provides a new molecular target and a solution for developing a WDR74 and ALYREF targeting medicine for treating esophageal squamous cell carcinoma and related diagnosis and prognosis evaluation products.

The invention discloses a traditional Chinese medicine composition for treating tumors. The invention belongs to the medical field of traditional Chinese medicine for treating tumors. The medicine consists of 21 traditional Chinese medicines such as artemisia anomala, pseudo-ginseng, pseudobulbus cremastrae seu pleiones, rhizoma paridis, dried alum, sal ammoniac and ground beeltle, and comprises plant medicines, mineral medicines and animal medicines. According to the theory that tumor formation is mostly caused by qi and blood stasis, phlegm-damp toxin and stagnation and accumulation and is essentially blood death, stubborn phlegm and rotten water, the traditional Chinese medicine composition is prepared by adopting the method of regulating qi, promoting blood circulation to remove blood stasis, softening hardness to dissipate stagnation, eliminating phlegm, dredging collaterals, clearing away heat and toxic materials, relieving pain, removing rotten water and inducing diuresis as well as strengthening body resistance to eliminate pathogenic factors according to the principle of syndrome differentiation and treatment of traditional Chinese medicine. The method is an empirical method gradually formed by continuous exploration in the practice process. The medicine has a treatment effect on tumors; the traditional Chinese medicine composition also has the effect of relieving and easing pain caused by tumors.

Provided are a tumor risk evaluation method and system. Specifically provided are a method and / or system for evaluating the correlation between a sample under test and a tumor formation risk and / or tumor tissue source. Methylation variation regions of various different cancers and specific methylation characteristic regions of various organs are captured by using DNA or RNA oligonucleotide sequences, the existence of tumor components (ctDNA) in blood cell-free DNA (cfDNA) is determined, and the correlation between the sample and the tumor tissue source is evaluated. Provided is a low-cost and high-accuracy method, which is conducive to accurately predicting and evaluating the risk of various cancers.

This invention provides a hypoxia-mediated mechanism of malignant tumor formation, a treatment simulation method, and a system, relating to the field of biomathematical modeling technology. The method includes: dividing the tumor into a core region and a peripheral region, defining the core differences between the two regions in their microenvironmental composition, and forming a conceptual interaction network; establishing a state variable system centered on the number of tumor cells, constructing a mathematical model integrating tumor core-periphery heterogeneity, hypoxia-mediated processes, and immunosuppression cycles; solving the mathematical model, calculating the changes of each state variable over time under different initial conditions or intervention parameters, and outputting simulation results characterizing tumor growth and the state of the immune microenvironment; this invention, through the multi-level regulation of cell proliferation, immunosuppression cycles, and angiogenesis signals by oxygen concentration gradients, more realistically reproduces the spatial heterogeneous growth dynamics of solid tumors in vivo, and simulates the formation and maintenance mechanism of a strong immunosuppressive state in the tumor core region.

The invention provides application of FOXL2 in preparation of a medicine for promoting differentiation or treating ovarian cancer. The FOXL2 action mechanism research with clearer and more complete evidence chain is carried out on the action of the FOXL2 in ovarian cancer, especially epithelial ovarian cancer by using large sample data, the effects of overexpression FOXL2 on tumor formation inhibition, differentiation promotion, metastasis inhibition and the like of ovarian cancer cells are effectively verified, and a new strategy is provided for treatment of ovarian cancer.

The invention discloses an application of a circRNA marker in diagnosis and treatment of colorectal cancer, the expression level of a circular RNA gene hsacirc0066801 in samples of patients with colorectal cancer and tumor cells is obviously improved, and the overexpression of the circular RNA hsacirc0066801 can obviously promote the proliferation, migration and invasion of the colorectal cancer cells. Meanwhile, knock-down of the hsacirc0066801 can significantly inhibit proliferation, migration and invasion of colorectal cancer cells, in addition, nude mouse tumor formation experiments prove that the tumor volume is significantly increased after overexpression of the hsacirc0066801, and is reduced after knock-down of the hsacirc0066801. Therefore, the hsacirc0066801 can be used as a potential molecular marker and is used as a target spot for clinical diagnosis and treatment of the colorectal cancer.

The invention relates to the field of biological medicines, in particular to application of fatty acid synthase (FASN) as a target spot in screening or preparing medicines for treating breast cancer, and particularly relates to targeted therapy for breast cancer stem cells (BCSCs). The invention discloses application of an FASN target spot in screening or preparing a medicine for treating breast cancer. Research finds that FASN is highly expressed in BCSCs, and stem cell characteristics of the BCSCs are maintained by activating a Wnt / beta-catenin pathway. By inhibiting the activity of FASN (such as using lansoprazole), the proliferation, self-renewal and tumor formation ability of BCSCs can be significantly reduced. The invention provides an FASN-based drug screening method and a drug composition, and provides a new strategy for breast cancer treatment.

The application provides a benzene [d] isoxazole compound and an application thereof. The compound has the structure shown in the following formula I. The benzene [d] isoxazole compound provided by the application can induce degradation of BET protein and / or GSPT1 protein, and has an anti-proliferation effect on cancer cells. Therefore, the compound and the composition provided by the application can be used for preparing a drug for treating or preventing tumor formation, inflammation, viral infection, cell proliferative disorder, autoimmune disease, sepsis and the like.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The present application relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of target immune drug for primary liver cancer and application thereof, wherein the combined marker is folate receptor gamma gene FOLR3, stratified protein gene SFN and coiled-coil domain containing 9 gene CCDC9 derived from peripheral blood leukocyte mRNA.The present application performs combined detection based on multiple peripheral blood leukocyte markers, and compared with a single molecular marker, can reduce errors caused by individual expression difference of a single index to some extent, so that the detection result is more accurate.The curative effect prediction model constructed based on detection of peripheral blood leukocyte mRNA level change can specifically recognize and detect in the early stage of tumor formation, has high sensitivity and high specificity, provides an important means for reasonable use of target immune drug for liver cancer patients sensitive or resistant to target immune drug, and has great significance for effective treatment of liver cancer in China.

The application provides an improved PDX model construction method and a reagent combination thereof, comprising a treatment method of patient tumor tissue after being separated from a body, an activation reagent during transplantation and mouse pretreatment, and the like. The method of the application can significantly shorten tumor formation days and improve tumor formation rate.

The invention discloses application of 3-bromo-1H-pyrrole-2, 5-diketone in preparation of a composition for treating esophageal squamous carcinoma, and is characterized in that the molecular formula of the 3-bromo-1H-pyrrole-2, 5-diketone is C4H2BrNO2, the molecular weight of the 3-bromo-1H-pyrrole-2, 5-diketone is 175.97, and the 3-bromo-1H-pyrrole-2, 5-diketone is derived from marine sponge Axinella brevista. The 3-bromo-1H-pyrrole-2, 5-diketone disclosed by the invention can effectively inhibit proliferation, migration, invasion and in-vivo tumor formation of esophageal squamous carcinoma cells, shows extremely low cytotoxicity, is remarkably superior to that of traditional chemotherapeutic drugs, and solves the technical problem that existing drugs for resisting esophageal squamous carcinoma are large in toxic and side effects.

The invention provides a small peptide for preventing and treating colon cancer and application thereof, and belongs to the technical field of biological medicine. Through structural simulation and functional verification, a polypeptide capable of specifically inhibiting G3BP1 lactylation in colon cancer cells in a targeted manner is screened out. The polypeptide inhibits the lactic acid modification level of G3BP1 by simulating a G3BP1 lactic acid recognition site and competitively combining with lactic acid enzyme, so that the G3BP1 mediated autophagy process is blocked, and finally proliferation and migration of colon cancer cells are inhibited. In-vitro cell experiments (including cell proliferation, migration and autophagy level analysis) and in-vivo transplantation tumor animal experiments prove that the oligopeptide can significantly inhibit growth and tumor formation of colon cancer cells. The discovery provides a new strategy and candidate drug molecules for molecular targeted therapy of colon cancer.

The application provides a kind of 2,6-piperidinedione derivatives and preparation method and application thereof.The compound has the structure shown in the following formula I, formula II or formula III:2,6-piperidinedione derivatives described in the application can induce the degradation of GSPT1 protein, and have cytotoxic effect on cancer cells.Therefore, the compound and composition provided by the application can be used for preparing drugs for treating or preventing tumor formation, inflammation, viral infection, cell proliferative disorder, autoimmune disease, sepsis and other related diseases.

The problem addressed by the present invention is to provide a method for efficiently producing highly safe cells, in which the Sendai virus vector has been removed and which do not cause adverse effects such as triggering tumor formation, from reversibly immortalized cells containing a Sendai virus vector. To this end, the present invention provides: a method for producing deimmortalized cells from reversibly immortalized cells comprising (1) a removal step for removing the Sendai virus vector from reversibly immortalized cells comprising animal cells that contain a Sendai virus vector containing an immortalization gene and (2) an isolation step for isolating the deimmortalized cells from which the Sendai virus vector has been removed from the cells after the removal step; deimmortalized cells produced by the method; and a regenerative medical product containing the immortalized cells.

The application provides application of indole acetic acid in intervention or treatment of thyroid cancer caused by long-term low-dose ionizing radiation, and belongs to the field of biomedical technology. It is found that indole acetic acid (IAA) is significantly negatively correlated with the occurrence of thyroid nodules after low-dose radiation, the proliferation, clone formation, invasion and migration of BCPAP cells can be inhibited after IAA is supplemented, and the tumor formation ability is greatly reduced, so the thyroid cancer caused by long-term low-dose ionizing radiation can be treated by supplementing IAA. The application also screens the KCNE4 gene for regulating the thyroid cancer caused by long-term low-dose ionizing radiation, and IAA can inhibit the expression of the gene, which indicates that IAA and the inhibitor of the gene both have the potential of serving as a therapeutic target for the thyroid cancer caused by long-term low-dose ionizing radiation.

The invention belongs to the technical field of tumor treatment, and particularly relates to a CRISPR library screening method of genes related to ovarian cancer cell growth, tumor formation and immune escape. The sgRNA library comprises sgRNA which is selected from 80 genes in a MusCK library in a targeting manner. According to the invention, a targeted MusCK library of 922 genes related to the starting, progression and immunoregulation of tumors is used, and a P53- / -Carm1OE Ccne1OE KrasOE mouse ovarian cancer cell line, a C57BL / 6 mouse and a BALB / c-nu mouse are respectively adopted for high-throughput screening, so that the immunoregulation of tumors is realized. A series of confirmed and unverified key genes for high-grade serous ovarian cancer cell growth, tumor formation and immune escape function exertion are successfully screened, and an important theoretical and experimental foundation is laid for finding a novel treatment target of the high-grade serous ovarian cancer; and breakthrough in targeted therapy of high-grade serous ovarian cancer is facilitated.

The invention discloses a method for preventing copper nodules from being formed at the edge of board-level packaging, which comprises the following steps of: forming a circle of ring with lateral erosion or undercutting, which protrudes upwards, at the edge of the top of a polyimide insulating layer by adopting a polyimide material in an exposure and over-development mode, and placing an electroplating clamp at the top of the polyimide insulating layer at the inner side of the ring for electroplating. According to the invention, through the arrangement of the ring protruding upwards, the seed layer is discontinuous in the sputtering process, so that current transmission is influenced; in addition, the exposure amount of the ring is reduced in the exposure process, so that the bottom of the ring is not sufficiently cured to form lateral erosion or undercutting under the attack of developing liquid, current transmission is further blocked, the electroplating clamp is arranged at the top of the polyimide insulating layer on the inner side of the ring for electroplating, and the ring is arranged to prevent the periphery of the electroplating clamp from conducting electricity so as not to grow copper nodules.

The application relates to the technical field of animal model construction, and particularly discloses a Sypl1 gene knockout colorectal cancer mouse model construction method and application, which comprises the following steps: synthesizing a specific target site gRNA of a Sypl1 gene, mixing Cas9 protein and the target site gRNA to obtain an injection compound, microinjecting the injection compound into mouse zygotes, and transplanting the surviving zygotes into the oviducts of pseudopregnant female mice to obtain F0 generation mice, and the mice born after 20 days are Sypl1 gene knockout mouse animal models; and a chemical induction modeling method is used to construct a colorectal cancer model in wild type mice and gene knockout mice. The Sypl1 gene knockout mouse is constructed by using a CRISPR / Cas mediated genome engineering technology Sypl1 combined with the most widely used colorectal cancer chemical inducer azoxymethane / dextran sodium sulfate, a new colorectal cancer mouse model is constructed, compared with a traditional chemical induction model, the tumor formation rate can be significantly improved, and the tumor formation time can be shortened, and a more efficient animal model is provided for colorectal cancer research.

Provided are a tumor risk evaluation method and system. Specifically provided are a method and / or system for evaluating the correlation between a sample under test and a tumor formation risk and / or tumor tissue source. Methylation variation regions of various different cancers and specific methylation characteristic regions of various organs are captured by using DNA or RNA oligonucleotide sequences, the existence of tumor components (ctDNA) in blood cell-free DNA (cfDNA) is determined, and the correlation between the sample and the tumor tissue source is evaluated. Provided is a low-cost and high-accuracy method, which is conducive to accurately predicting and evaluating the risk of various cancers.

The invention relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of a primary hepatocellular carcinoma target-free drug and application of the combined marker, and the combined marker is a folate receptor gamma gene FOLR3 derived from peripheral blood leucocyte mRNA, a layered protein gene SFN and a coiled-coil domain protein 9 gene CCDC9. According to the invention, combined detection is carried out based on a plurality of peripheral blood leucocyte markers, and compared with a single molecular marker, errors caused by individual expression difference of a single index can be reduced to a certain extent, so that the detection result is more accurate. The curative effect prediction model constructed based on detection of peripheral blood leucocyte mRNA level change can perform specific recognition detection in the initial stage of tumor formation, has high sensitivity and high specificity, and provides an important means for reasonable medication of hepatocellular carcinoma patients sensitive or resistant to target-free drugs. The important significance is realized on the effective treatment of the hepatocellular carcinoma in China.

The application provides a small peptide for preventing and treating colon cancer and an application thereof, and belongs to the technical field of biological medicine. Through structure simulation and function verification, a polypeptide capable of specifically targeting and inhibiting G3BP1 lactylation in colon cancer cells is screened. The polypeptide competitively binds to lactylase by simulating the G3BP1 lactylation recognition site, thereby inhibiting the lactylation modification level of G3BP1, blocking the autophagy process mediated by G3BP1, and finally inhibiting the proliferation and migration of colon cancer cells. Through in vitro cell experiments (including cell proliferation, migration and autophagy level analysis) and in vivo tumor transplantation animal experiments, it is proved that the short peptide can significantly inhibit the growth and tumor formation of colon cancer cells. This finding provides a new strategy and candidate drug molecule for the molecular targeted treatment of colon cancer.

The invention discloses a macaque skin squamous carcinoma cell line MCSCC14397 and application of the macaque skin squamous carcinoma cell line MCSCC14397. The macaque skin squamous carcinoma cell line is named as macaque skin squamous carcinoma cell line MCSCC14397, and the preservation number of the macaque skin squamous carcinoma cell line is CCTCC (China Center For Type Culture Collection) NO: C2025156. The cell line disclosed by the invention has similar protein expression with primary tumor tissues, has chromosome abnormal karyotype, in-vitro tumor formation capability and stable proliferation characteristics, and simultaneously shows remarkable genome instability (such as high-frequency Cgt, T mutation and structural variation) and inflammation signal activation. The MYO10 gene expression in the cell line is up-regulated and drives DNA damage reaction and inflammatory factor expression, and unique advantages are provided for application of the cell line in skin squamous cell carcinoma mechanism research, drug screening and drug efficacy evaluation. The cell line disclosed by the invention can be used as an effective cell model, can be used for establishing a xenotransplantation animal model, and can provide a research basis for deeply researching the occurrence, development, metastasis mechanism and drug resistance mechanism of human skin squamous cell carcinoma as well as innovative drug development and screening.

The invention relates to the technical field of animal model construction, and particularly discloses a construction method and application of a Sypl1 gene knockout colorectal cancer mouse model, and the construction method comprises the following steps: synthesizing a specific target site gRNA of a Sypl1 gene, uniformly mixing Cas9 protein and the target site gRNA to obtain an injection compound, microinjecting the injection compound into a mouse fertilized egg to obtain a Sypl1 gene knockout colorectal cancer mouse model. And transplanting the survival fertilized ova into the salpingtube of a pseudopregnant female mouse for 20 days to obtain a mouse which is an F0-generation mouse, obtaining a Sypl1 gene knockout mouse animal model, and constructing a colorectal cancer model in a wild type mouse and a gene knockout mouse by adopting a chemical induction modeling method. A Sypl1 gene knockout mouse is constructed through a CRISPR / Cas mediated genome engineering technology, a novel colorectal cancer mouse model is constructed in combination with a colorectal cancer chemical inducer azomethane / dextran sodium sulfate which is most widely applied at present, and compared with a traditional chemical induction model, the novel colorectal cancer mouse model has the advantages that the tumor formation rate can be remarkably increased, the tumor formation time can be shortened, and the tumor formation cost can be reduced. And a more efficient animal model is provided for colorectal cancer research.

The invention provides a medicine for targeting early-stage precursor T cell acute lymphocytic leukemia (ETP-ALL) and application of the medicine. Dichloroacetic acid (DCA) is used for regulating mitochondrial oxidative phosphorylation, so that electron transport chain flux can be enhanced, ROS (reactive oxygen species) generation can be promoted, endoplasmic reticulum stress related pathways can be activated, the proliferation states of an ETP-ALL leukemia cell line and a primary patient sample can be influenced, and cell apoptosis can be induced. In cell line-derived and patient-derived xenograft models, DCA treatment can reduce leukemia load in bone marrow, spleen and peripheral blood and affect tumor formation characteristics. DCA shows good tolerance in normal hematopoietic system and other leukemia models. The method provides a treatment strategy based on metabolism targeted regulation, and provides a potential technical route and application reference for ETP-ALL research and drug development.

A method for predicting an association relationship between a sample and a tumor, a device, a medium and a program. The method comprises: acquiring methylation detection data about a sample under test, the methylation detection data at least indicating information of CpG sites covered by a cfDNA fragment and methylation status data of the CpG sites; on the basis of the information of the CpG sites, determining from amongst a plurality of methylation level templates a target methylation level template associated with the cfDNA fragment; on the basis of a plurality of methylation status models associated with the target methylation level template and the methylation status data of the CpG sites covered by the cfDNA fragment, generating regional methylation features; and, on the basis of the regional methylation features, by means of a first classification model trained on the basis of sample data, generating a predicted result for indicating an association relationship between said sample and one or more tumors. The present invention can conveniently, precisely and comprehensively predict tumor formation risks or tumor tissue sources of samples under test.

The present invention relates to anti-CXCR2 antibodies and uses thereof. The anti-CXCR2 antibody or the antigen-binding fragment thereof according to the present invention can specifically bind to cancer cells expressing CXCR2, and exhibits an anti-tumor effect by inhibiting a CXCL8 / CXCR2 signaling pathway that plays an important role in tumor formation and growth, and thus can be effectively used for treating cancer patients in which CXCR2 is overexpressed. In addition, the anti-CXCR2 antibody or the antigen-binding fragment thereof according to the present invention specifically binds to CXCR2, thereby enabling the diagnosis of cancer in which CXCR2 is overexpressed.

The invention provides an application of paraclostridium graciliatum in preparation of a medicine for treating colorectal cancer. According to the present invention, the culture supernatant of the Paracostridium tenue CGMCC No.31232 can effectively inhibit the proliferation, the clone formation and the migration of the colorectal cancer cells, promote the apoptosis of the colorectal cancer cells, and induce the cell cycle arrest; a colorectal cancer transplanted tumor mouse model verifies that the strain can inhibit tumor formation of a colorectal cancer transplanted tumor mouse, regulate intestinal microbiota, influence the expression of immune factors in tumors and generate metabolites with an anti-CRC effect, has the effect of improving the colorectal cancer of the mouse, has no obvious toxic or side effect on animals, and can be used for preparing a medicine for treating the colorectal cancer of the mouse. The invention provides a new strategy for treatment of colorectal cancer, and has a potential clinical application prospect.